254 related articles for article (PubMed ID: 17936848)
21. Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
Mardjuadi F; Medioni J; Kerger J; D'Hondt L; Canon JL; Duck L; Musuamba F; Oudard S; Clausse M; Moxhon A; Machiels JP
Cancer Chemother Pharmacol; 2012 Aug; 70(2):293-303. PubMed ID: 22752248
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer.
Trump DL; Potter DM; Muindi J; Brufsky A; Johnson CS
Cancer; 2006 May; 106(10):2136-42. PubMed ID: 16598750
[TBL] [Abstract][Full Text] [Related]
23. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA
Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319
[TBL] [Abstract][Full Text] [Related]
24. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Garrett-Mayer E; de Wit R; Tannock I; Eisenberger M
Clin Cancer Res; 2010 Jan; 16(1):203-11. PubMed ID: 20008841
[TBL] [Abstract][Full Text] [Related]
25. An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.
Pezaro C; Rosenthal MA; Gurney H; Davis ID; Underhill C; Boyer MJ; Kotasek D; Solomon B; Toner GC
Am J Clin Oncol; 2009 Aug; 32(4):338-41. PubMed ID: 19363437
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.
Hellerstedt B; Pienta KJ; Redman BG; Esper P; Dunn R; Fardig J; Olson K; Smith DC
Cancer; 2003 Oct; 98(8):1603-10. PubMed ID: 14534875
[TBL] [Abstract][Full Text] [Related]
27. [Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].
Bao L; Lu XJ; Zhang XH; Huang XJ
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1829-31. PubMed ID: 19040018
[TBL] [Abstract][Full Text] [Related]
28. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
29. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
[TBL] [Abstract][Full Text] [Related]
30. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
Morris MJ; Smaletz O; Solit D; Kelly WK; Slovin S; Flombaum C; Curley T; Delacruz A; Schwartz L; Fleisher M; Zhu A; Diani M; Fallon M; Scher HI
Cancer; 2004 May; 100(9):1868-75. PubMed ID: 15112267
[TBL] [Abstract][Full Text] [Related]
31. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer.
Slovin SF; Kelly WK; Wilton A; Kattan M; Myskowski P; Mendelsohn J; Scher HI
Clin Genitourin Cancer; 2009 Oct; 7(3):E77-82. PubMed ID: 19815486
[TBL] [Abstract][Full Text] [Related]
32. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer MJ
Intern Med J; 2005 Aug; 35(8):468-72. PubMed ID: 16176469
[TBL] [Abstract][Full Text] [Related]
33. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Lara PN; Stadler WM; Longmate J; Quinn DI; Wexler J; Van Loan M; Twardowski P; Gumerlock PH; Vogelzang NJ; Vokes EE; Lenz HJ; Doroshow JH; Gandara DR
Clin Cancer Res; 2006 Mar; 12(5):1556-63. PubMed ID: 16533781
[TBL] [Abstract][Full Text] [Related]
34. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
Ernst DS; Tannock IF; Winquist EW; Venner PM; Reyno L; Moore MJ; Chi K; Ding K; Elliott C; Parulekar W
J Clin Oncol; 2003 Sep; 21(17):3335-42. PubMed ID: 12947070
[TBL] [Abstract][Full Text] [Related]
35. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
Maki RG; Kraft AS; Scheu K; Yamada J; Wadler S; Antonescu CR; Wright JJ; Schwartz GK
Cancer; 2005 Apr; 103(7):1431-8. PubMed ID: 15739208
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of bortezomib for patients with advanced renal cell carcinoma.
Kondagunta GV; Drucker B; Schwartz L; Bacik J; Marion S; Russo P; Mazumdar M; Motzer RJ
J Clin Oncol; 2004 Sep; 22(18):3720-5. PubMed ID: 15365068
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
38. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Meluch AA; Spigel DR; Barton J; Simons L; Meng C; Gould B; Greco FA
Clin Genitourin Cancer; 2007 Mar; 5(4):278-83. PubMed ID: 17553208
[TBL] [Abstract][Full Text] [Related]
39. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
Chi KN; Hotte SJ; Yu EY; Tu D; Eigl BJ; Tannock I; Saad F; North S; Powers J; Gleave ME; Eisenhauer EA
J Clin Oncol; 2010 Sep; 28(27):4247-54. PubMed ID: 20733135
[TBL] [Abstract][Full Text] [Related]
40. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
